tbuckley/cabot-search huggingface dataset:
Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer
Authors: Dongbing Zhao, Pinli Yue, Tongbo Wang, Pei Wang, Qianqian Song, Jingjing Wang, Yuchen Jiao
Journal: Journal of Hematology & Oncology (2021)

Peritoneal dissemination (PD) is a major type of gastric cancer (GC) recurrence and leads to rapid death. Current approaches cannot precisely determine which patients are at high risk of PD to provide early intervention. In this study, we developed a technology to detect minimal residual cancer cells in peritoneal lavage fluid (PLF) samples with a personalized assay profiling tumor-specific mutations. In a prospective cohort of 104 GC patients, the technology detected all the cases that developed PD with 100% sensitivity and 85% specificity. The minimal residual cancer cells in PLF were associated with a significantly increased risk of PD (HR = 145.13; 95% CI 20.20-18,435.79; p < 0.001), which was the strongest independent predictor over pathologic diagnosis and cytological diagnosis. In pathologically high-risk (pT4) patients, the PLF mutation profiling model exhibited a greater specificity of 91% and a positive predictive value of 88% while retaining a sensitivity of 100%. This approach may help in the postsurgical management of GC patients by detecting PD far before metastatic lesions grow to a significant size detectable by conventional methods such as MRI and CT scanning.
Contact Precautions and Methicillin-Resistant <i>Staphylococcus aureus—</i>Modeling Our Way to Safety
Authors: Michihiko Goto, Anthony D. Harris, Eli N. Perencevich
Journal: JAMA Network Open (2021)

Karim Khader, PhD; Alun Thomas, PhD; Vanessa Stevens, PhD; Lindsay Visnovsky, PhD; McKenna Nevers, MS; Damon Toth, PhD; Lindsay T. Keegan, PhD; Makoto Jones, MD; Michael Rubin, PhD, MD; Matthew H. Samore, MD
Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial
Authors: Aurélien Dinh, Jacques Ropers, Clara Duran, Benjamin Davido, Laurène Deconinck, Morgan Matt, Olivia Senard, Aurore Lagrange, Sabrina Makhloufi, Guillaume Mellon, Victoire de Lastours, Frédérique Bouchand, Emmanuel Mathieu, Jean-Emmanuel Kahn, Elisabeth Rouveix, Julie Grenet, Jennifer Dumoulin, Thierry Chinet, Marion Pépin, Véronique Delcey, Sylvain Diamantis, Daniel Benhamou, Virginie Vitrat, Marie-Christine Dombret, Bertrand Renaud, Christian Perronne, Yann-Erick Claessens, José Labarère, Jean-Pierre Bedos, Philippe Aegerter, Anne-Claude Crémieux, Julie ATTAL-BEHAR, Sébastien BEAUNE, Thierry CHINET, Tristan CUDENNEC, Marine DE LAROCHE, Albane DE THEZY, Jennifer DUMOULIN, Caroline DUPONT, Elise FERCOT, Violaine GIRAUT, Ségolène GREFFE, Julie GRENET, Caroline GUYOT, Jean-Emmanuel KAHN, Sylvie LABRUNE, Marie LACHATRE, Sophie MOULIAS, Charlotte NALINE, Marion PEPIN, Elisabeth ROUVEIX, Marine SAHUT-D'IZARN, Abel SEFSSAFI, Laurent TEILLET, Jean-Pierre BRU, Jacques GAILLAT, Vincent GAUTIER, Cécile JANSSEN, Leonardo PAGANI, Virginie VITRAT, Malika ABDERRAHMANE, Juliette CAMUSET, Catherine LEGALL, Pascale LONGUET-FLANDRES, Anne-Marie MENN, Victoire DE LASTOURS, Marie LECRONIER, Gwenolée PREVOST, Charles BURDET, Ouda DERRADJI, Lelia ESCAUT, Etienne HINGLAIS, Philippe LEBRAS, Edouard LEFEVRE, Mathilde NOAILLON, Pauline RABIER, Maurice RAPHAEL, Elina TEICHER, Christiane VERNY, Daniel VITTECOQ, Benjamin WYPLOSZ, Michèle BEN HAYOUN, Françoise BRUN-VEZINET, Enrique CASALINO, Christophe CHOQUET, Marie-Christine DOMBRET, Xavier DUVAL, Nadhira HOUHOU, Véronique JOLY, Xavier LESCURE, Manuela POGLIAGHI, Christophe RIOUX, Yazdan YAZDANPANAH, Elsa BARROS, Belinda BEGGA, Sébastien BOUKOBZA, Houria BOUREDJI, Imad CHOUAHI, Isabelle DELACROIX, Antoine FROISSART, Valérie GARRAIT, Elsa NGWEM, Catherine PHLIPPOTEAU, Sepehr SALEHABADI, Cécile TOPER, Florent VINAS, Marie AMSILLI, Olivier EPAULARD, Patricia PAVESE, Isabelle PIERRE, Jean-Paul STAHL, Jérôme AULAGNIER, Julie CELERIER, Roxana COJOCARIU, Emmanuel MATHIEU, Charlotte RACHLINE, Yoland SCHOINDRE, Thomas SENE, Christelle THIERRY, Caroline APARICIO, Véronique DELCEY, Amanda LOPES, Marjolaine MORGAND, Pierre SELLIER, Guy SIMONEAU, Catherine CHAKVETADZE, Sylvain DIAMANTIS, Arnaud GAUTHIER, Kaoutar JIDAR, Béatrice JOURDAIN, Jean-Francois BOITIAUX, Patrick DESCHAMPS, Edouard DEVAUD, Bruno PHILIPPE, Ruxandra-Oana CALIN, Tomasz CHROBOCZEK, Benjamin DAVIDO, Laurène DECONINCK, Pierre DE TRUCHIS, Aurore LAGRANGE, Sabrina MAKHLOUFI, Morgan MATT, Guillaume MELLON, Olivia SENARD, Daniel BENHAMOU, Claire CHAPUZET, Laure CHAUFFREY, Manuel ETIENNE, Luc-Marie JOLY, Bérengère OBSTOY, Mathieu SALAUN, Luc THIBERVILLE, Julie TILLON, Diane BOLLENS, Julie BOTTERO, Pauline CAMPA, Gäelle COSQUERIC, Bénédicte LEFEBVRE, Zineb OUAZENE, Jérôme PACANOWSKI, Dominique PATERON, Nadia VALIN, Caroline COMPAIN, Hugues CORDEL, Benoit DOUMENC, Elena FOIS, Nicolas GAMBIER, Marie-Aude KHUONG, Elisa PASQUALONI, Marie POUPARD
Journal: The Lancet (2021)
P01.07 Real World Outcomes of Advanced Non-Small Cell Lung Cancer (NSCLC) With Attention to Carboplatin Area Under the Curve (AUC) = 5 Versus 6
Authors: L. Fitzgerald, J. Sinnott, A. Trunk, A. Chalmers, W. Akerley, S. Patel
Journal: Journal of Thoracic Oncology (2021)
P71.02 Estrogen Promotes Resistance to Bevacizumab Treatment in Non-Small Cell Lung Cancer (NSCLC) Xenograft Models
Authors: S. Patel, M. Herynk, T. Cascone, B. Saigal, M. Nilsson, H. Tran, S. Ramachandran, J. Minna, I. Wistuba, J. Heymach
Journal: Journal of Thoracic Oncology (2021)
The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis
Authors: Michelle Bosman, Sigrid Elsenbruch, Maura Corsetti, Jan Tack, Magnus Simrén, Bjorn Winkens, Thimo Boumans, Ad Masclee, Daniel Keszthelyi
Journal: The Lancet. Gastroenterology & hepatology (2021)
GPR15 Facilitates Recruitment of Regulatory T Cells to Promote Colorectal Cancer
Authors: Alexandra Adamczyk, Eva Pastille, Jan Kehrmann, Vivian P. Vu, Robert Geffers, Marie-Hélène Wasmer, Stefan Kasper, Martin Schuler, Christian M. Lange, Beat Muggli, Tilman T. Rau, Diana Klein, Wiebke Hansen, Philippe Krebs, Jan Buer, Astrid M. Westendorf
Journal: Cancer Research (2021)

Abstract Colorectal cancer is one of the most frequent malignancies worldwide. Despite considerable progress in early detection and treatment, there is still an unmet need for novel antitumor therapies, particularly in advanced colorectal cancer. Regulatory T cells (Treg) are increased in the peripheral blood and tumor tissue of patients with colorectal cancer. Recently, transient ablation of tumor-associated Tregs was shown to foster CD8+ T-cell–mediated antitumoral immunity in murine colorectal cancer models. However, before considering therapies on targeting Tregs in patients with cancer, detailed knowledge of the phenotype and features of tumor-associated Tregs is indispensable. Here, we demonstrate in a murine model of inflammation-induced colorectal cancer that tumor-associated Tregs are mainly of thymic origin and equipped with a specific set of molecules strongly associated with enhanced migratory properties. Particularly, a dense infiltration of Tregs in mouse and human colorectal cancer lesions correlated with increased expression of the orphan chemoattractant receptor GPR15 on these cells. Comprehensive gene expression analysis revealed that tumor-associated GPR15+ Tregs have a Th17-like phenotype, thereby producing IL17 and TNFα. Gpr15 deficiency repressed Treg infiltration in colorectal cancer, which paved the way for enhanced antitumoral CD8+ T-cell immunity and reduced tumorigenesis. In conclusion, GPR15 represents a promising novel target for modifying T-cell–mediated antitumoral immunity in colorectal cancer. Significance: The G protein–coupled receptor 15, an unconventional chemokine receptor, directs Tregs into the colon, thereby modifying the tumor microenvironment and promoting intestinal tumorigenesis. See related commentary by Chakraborty and Zappasodi, p. 2817
FP05.03 Association between Baseline Tumor Thickness and Response to Neoadjuvant Chemotherapy in Malignant Pleural Mesothelioma
Authors: N. Zhou, D. Rice, R. Mehran, H. Feldman, K. Tomczak, W. Hofstetter, A. Vaporciyan, A. Correa, J. Zhang, C. Haymaker, A. Tsao, B. Sepesi
Journal: Journal of Thoracic Oncology (2021)
Single-cell melanoma transcriptomes depicting functional versatility and clinical implications of STIM1 in the tumor microenvironment
Authors: Henry Sung-Ching Wong, Wei-Chiao Chang
Journal: Theranostics (2021)

Rationale: Previous studies have implicated the functions of stromal interaction molecule 1 (STIM1) in immunity and malignancy, however, the specificity and effects of STIM1 expression in malignant and non-malignant cells in the tumor microenvironment are unclear. Methods: In the current study, we posed two central questions: (1) does STIM1 expression elicit different cellular programs in cell types within the melanoma tumor microenvironment (2) whether the expression of STIM1 and STIM1-coexpressed genes (SCGs) serve as prognostic indicators of patient's outcomes? To answer these questions, we dissected cell-specific STIM1-associated cellular programs in diverse cell types within the melanoma tumor microenvironment by measuring cell-type specificity of STIM1 expression and SCGs. Results: A distinct set of SCGs was highly affected in malignant melanoma cells, but not in the other cell types, suggesting the existence of malignant-cell-specific cellular programs reflected by STIM1 expression. In contrast to malignant cells, STIM1 expression appeared to trigger universal and non-specific biological functions in non-malignant cell types, as exemplified by the transcriptomes of macrophages and CD4+ T regulatory cells. Results from bioinformatic analyses indicated that SCGs in malignant cells may alter cell-cell interactions through cytokine/chemokine signaling and/or orchestrate immune infiltration into the tumor. Moreover, a prognostic association between SCGs in CD4+ T regulatory cells and patient's outcomes was identified. However, we didn't find any correlation between SCGs and responsiveness of immunotherapy. Conclusions: Overall, our results provide an integrated biological framework for understanding the functional and clinical consequences of cell-specific STIM1 expression in melanoma.
Secretory products of the corpus luteum and preeclampsia
Authors: María M Pereira, Monica Mainigi, Jerome F Strauss
Journal: Human Reproduction Update (2021)

Despite significant advances in our understanding of the pathophysiology of preeclampsia (PE), there are still many unknowns and controversies in the field. Women undergoing frozen-thawed embryo transfer (FET) to a hormonally prepared endometrium have been found to have an unexpected increased risk of PE compared to women who receive embryos in a natural FET cycle. The differences in risk have been hypothesized to be related to the absence or presence of a functioning corpus luteum (CL).
P38.10 Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: A Single-Center Experience
Authors: L. Ventura, L. Gnetti, M. Rossi, M. Tiseo, M. Silva, N. Sverzellati, E. Silini, C. Braggio, V. Costantino, G. Bocchialini, L. Musini, S. Cattadori, V. Balestra, M. Rusca, P. Carbognani, L. Ampollini
Journal: Journal of Thoracic Oncology (2021)
P84.12 Complete Response to Alectinib Following Crizotinib in an ALK-Rearranged Metastatic Inflammatory Myofibroblastic Tumor
Authors: C. Xavier, F. Canedo, F. Lima, R. Melo, L.G. Lima, J.F. Marin, C. Souza, O. Feher
Journal: Journal of Thoracic Oncology (2021)
Endotype of allergic asthma with airway obstruction in urban children
Authors: Matthew C. Altman, Agustin Calatroni, Sima Ramratnam, Daniel J. Jackson, Scott Presnell, Mario G. Rosasco, Peter J. Gergen, Leonard B. Bacharier, George T. O’Connor, Megan T. Sandel, Meyer Kattan, Robert A. Wood, Cynthia M. Visness, James E. Gern
Journal: Journal of Allergy and Clinical Immunology (2021)
P14.11 Optimal Combination of Biomarkers to Improve the Predictive Value of Immunotherapeutic Response in Non-Small Cell Lung Cancer
Authors: S. Kwon, H.J. Kwon, E.S. Kim, K.J. Suh, S.H. Kim, Y.J. Kim, J. Lee, J. Chung, H. Kim
Journal: Journal of Thoracic Oncology (2021)
Discovery of New Protein Targets of BPA Analogs and Derivatives Associated with Noncommunicable Diseases: A Virtual High-Throughput Screening
Authors: Diana Montes-Grajales, Xiomara Morelos-Cortes, Jesus Olivero-Verbel
Journal: Environmental Health Perspectives (2021)

Background: Bisphenol A analogs and derivatives (BPs) have emerged as new contaminants with little or no information about their toxicity. These have been found in numerous everyday products, from thermal paper receipts to plastic containers, and measured in human samples. Objectives: The objectives of this research were to identify in silico new protein targets of BPs associated with seven noncommunicable diseases (NCDs), and to study their protein–ligand interactions using computer-aided tools. Methods: Fifty BPs were identified by a literature search and submitted to a virtual high-throughput screening (vHTS) with 328 proteins associated with NCDs. Protein–protein interactions between predicted targets were examined using STRING, and the protocol was validated in terms of binding site recognition and correlation between in silico affinities and in vitro data. Results: According to the vHTS, several BPs may target proteins associated with NCDs, some of them with stronger affinities than bisphenol A (BPA). The best affinity score (the highest in silico affinity absolute value) was obtained after docking 4,4′-bis(N-carbamoyl-4-methylbenzensulfonamide)diphenylmethane (BTUM) on estradiol 17-beta-dehydrogenase 1 (−13.7 kcal/mol). However, other molecules, such as bisphenol A bis(diphenyl phosphate) (BDP), bisphenol PH (BPPH), and Pergafast 201 also exhibited great affinities (top 10 affinity scores for each disease) with proteins related to NCDs. Discussion: Molecules such as BTUM, BDP, BPPH, and Pergafast 201 could be targeting key signaling pathways related to NCDs. These BPs should be prioritized for in vitro and in vivo toxicity testing and to further assess their possible role in the development of these diseases. https://doi.org/10.1289/EHP7466
<i>JAMA Psychiatry</i>—The Year in Review, 2020
Authors: Dost Öngür
Journal: JAMA Psychiatry (2021)

I have been involved in writing, starting with a piece written jointly with my predecessor, Stephan Heckers, MD, MSc, in 2017.I had no idea what kind of article this would be when the year started; in fact, none of us could have imagined then the world we are living in now.The coronavirus disease 2019 (COVID-19) pandemic has claimed many lives and disrupted countless more, surely including those of many readers.I wish the whole world a rapid recovery from this pandemic.2][3][4][5] Our journal became more selective than ever because the number of articles we publish did not rise with the explosion in submissions; in 2020, we accepted 5% of all submitted research manuscripts.We still were able to reject manuscripts without peer review with a median turnaround time of 1 day so that authors could submit their work elsewhere quickly.We also maintained a fast pace for peer-reviewed manuscripts, with a median of 34 days from receipt to first decision with peer review.I am proud of our team for maintaining these high standards in the midst of a pandemic and with substantially greater volume of submitted manuscripts than ever before.Our goal through all of this remains improving the experience of our authors who submit their best work to JAMA Psychiatry.We made the decision early on in the pandemic that we would publish high-impact COVID-19-related articles that would stand the test of time.By this we had in mind Original Investigations that presented data on important trends related to psychiatry and mental health in the pandemic and shorter Viewpoints that explored major themes.We published a relatively small number of such articles in 2020, minute in comparison with the huge number of manuscripts submitted to our journal on this topic, and we intend to continue a similar trend in the new year.At JAMA Psychiatry, we are committed to increasing diversity and inclusion of underrepresented voices in the field.We always welcome contributions from investigators from underrepresented backgrounds and on topics related to disparities in psychiatry.We reach out to such individuals and solicit submissions as appropriate.In 2021, we hope to publish more articles on care delivery and outcomes associated with racial/ethnic disparities and other disparities; we will also focus on articles describing interventions designed to reduce such differences and on global mental health problems.We also
Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia
Authors: Mari Hashimoto, Yoriko Saito, Ryo Nakagawa, Ikuko Ogahara, Shinsuke Takagi, Sadaaki Takata, Hanae Amitani, Mikiko Endo, Hitomi Yuki, Jordan A. Ramilowski, Jessica Severin, Ri-ichiroh Manabe, Takashi Watanabe, Kokoro Ozaki, Akiko Kaneko, Hiroshi Kajita, Saera Fujiki, Kaori Sato, Teruki Honma, Naoyuki Uchida, Takehiro Fukami, Yasushi Okazaki, Osamu Ohara, Leonard D. Shultz, Makoto Yamada, Shuichi Taniguchi, Paresh Vyas, Michiel de Hoon, Yukihide Momozawa, Fumihiko Ishikawa
Journal: Nature Cancer (2021)
Stereotactic Ablative Body Radiotherapy for Metastases Needs Better Evidence
Authors: Fergus R. Macbeth, Raymond P. Abratt
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
慢性骨髄性白血病(First-line DADI試験)患者におけるファーストラインダサチニブ中止後の無治療寛解:単一腕多施設第2相試験【JST・京大機械翻訳】
Authors: Kimura Shinya, Imagawa Jun, Murai Kazunori, Hino Masayuki, Kitawaki Toshio, Okada Masaya, Tanaka Hideo, Shindo Motohiro, Kumagai Takashi, Ikezoe Takayuki, Uoshima Nobuhiko, Sato Tsutomu, Watanabe Reiko, Kowata Shugo, Hayakawa Masaya, Hosoki Takaaki, Ikeda Kazuhiko, Kobayashi Tsutomu, Kakinoki Yasutaka, Nishimoto Tetsuo, Takezako Naoki, Shibayama Hirohiko, Takaori-Kondo Akifumi, Nakamae Hirohisa, Kawaguchi Atsushi, Ureshino Hiroshi, Sakamoto Junichi, Ishida Yoji
Journal: The Lancet Haematology (2020)
Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria
Authors: Yuan Liu, Ziwen Tong, Jingru Shi, Ruichao Li, Mathew Upton, Zhiqiang Wang
Journal: Theranostics (2021)

Antimicrobial resistance has been a global health challenge that threatens our ability to control and treat life-threatening bacterial infections. Despite ongoing efforts to identify new drugs or alternatives to antibiotics, no new classes of antibiotic or their alternatives have been clinically approved in the last three decades. A combination of antibiotics and non-antibiotic compounds that could inhibit bacterial resistance determinants or enhance antibiotic activity offers a sustainable and effective strategy to confront multidrug-resistant bacteria. In this review, we provide a brief overview of the co-evolution of antibiotic discovery and the development of bacterial resistance. We summarize drug-drug interactions and uncover the art of repurposing non-antibiotic drugs as potential antibiotic adjuvants, including discussing classification and mechanisms of action, as well as reporting novel screening platforms. A pathogen-by-pathogen approach is then proposed to highlight the critical value of drug repurposing and its therapeutic potential. Finally, general advantages, challenges and development trends of drug combination strategy are discussed.
Updated Information About Index Patient in Study of SARS-CoV-2 Transmission Among Bus Riders in Eastern China
Authors: Srishti Saha, Piyush Nathani, Arjun Gupta
Journal: JAMA Internal Medicine (2021)

Ye Shen, PhD; Changwei Li, PhD; Hongjun Dong, MD; Zhen Wang, MD; Leonardo Martinez, PhD; Zhou Sun, MD; Andreas Handel, PhD; Zhiping Chen, MD; Enfu Chen, MD; Mark H. Ebell, MD, MS; Fan Wang, MA; Bo Yi, MD; Haibin Wang, MD; Xiaoxiao Wang, MD; Aihong Wang, MD; Bingbing Chen, MD; Yanling Qi, PhD; Lirong Liang, MD, PhD; Yang Li, PhD; Feng Ling, MD; Junfang Chen, MD; Guozhang Xu, MD
P03.01 A Randomized Phase II Trial of Adjuvant Pembrolizumab vs Observation after Curative Resection for Stage I NSCLC with Primary Tumors Between 1-4 cm
Authors: G. Durm, T. Birdas, H. Liu, S. Jalal, K. Kesler, K. Rieger, D. Ceppa, N. Hanna
Journal: Journal of Thoracic Oncology (2021)
Variation of Blood Pressure and Sympathetic Nerve Acvitiy in Essential Hypertension with Neurovascular Compression of the Rostral Ventrolateral Medulla
Authors: Sumi Shunichiro, Inoue Yukiko, Miyoshi Kei, Matsumoto Kenzo, Maruyama Seiyo, Fukuda Yusuke, Furuyama Shodai, Andoh Chie, Kubota Kazumitsu, Tohjoh Hideaki, Yamanouchi Yoshio, Urata Hidenori
Journal: Circulation (2010)